This study looks at treating a type of cancer called rhabdomyosarcoma (RMS), which often comes back or spreads. It compares two groups of patients to see which treatment works better. One group receives a drug called vinorelbine along with other chemotherapy drugs: vincristine, dactinomycin, and cyclophosphamide. These drugs work by stopping cancer cells from growing and dividing. After initial treatment, patients may receive "maintenance therapy" to try and keep the cancer away. Maintenance therapy includes vinorelbine and cyclophosphamide. This study involves regular check-ups and imaging tests like CT or MRI scans to monitor progress. The trial aims to find the best way to keep RMS from returning or spreading.

• Duration: The study involves regular treatment cycles over several months, followed by maintenance therapy.
• Participation: Patients must be under 50 years old, with newly diagnosed RMS, and meet specific health criteria.
• Follow-Up: Patients will be monitored for up to 5 years after treatment to assess long-term outcomes.